Isotretinoin exposure and pregnancy outcome: an observational study of the Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy
- 1.2k Downloads
Apart from thalidomide, retinoids like isotretinoin are the strongest teratogens in humans known today. The overall risk of birth defects is estimated as up to 30% after exposure during embryogenesis. In spite of well established pregnancy prevention programs, pregnancies still occur during isotretinoin therapy in many countries including Germany. A detailed investigation of the incidence and outcome of these pregnancies would fill an important gap.
The Berlin Institute for Clinical Teratology documents prospectively the course of drug-exposed pregnancies when contacted for individual drug risk assessment. Datasets of isotretinoin exposed pregnancies recorded between 1993 and 2008 were evaluated as to the outcome of pregnancy.
A total of 108 pregnancies exposed to systemic isotretinoin (median dosage 20 mg/day) during the contraindicated period were registered. 76% (69/91) of the pregnancies with known outcome were electively terminated—mainly for fear of medication risk. No terminations due to abnormal prenatal ultrasound findings were reported. Spontaneous abortions occurred in five pregnancies. Of 18 live births including 1 pair of twins 1 major birth defect (small ventricular septal defect) was observed. None of the infants showed symptoms of retinoid embryopathy. 70% (48/69) of the patients with data on contraception did not use any method, in 30% contraception failed. There was no evidence that poor maternal education was a major cause for the omission of contraception documented in 48 women.
Inadvertent isotretinoin exposure during the first 2 weeks post conception does not necessarily require discussion of termination of pregnancy, as the risk of major birth defects appears to be much lower than it becomes beyond this period. Nevertheless, additional efforts are required to improve the effectiveness of contraception while on isotretinoin treatment considering psycho-social aspects such as improved self-confidence, unexpected new partnership and sexual activity and incorrect perception of infertility.
KeywordsIsotretinoin Retinoids Pregnancy Acne Contraception Fetal outcome Pregnancy outcome Teratogenicity
The authors thank Dr. Dorothy Rosenberg, Maine, USA, for critical reading of the manuscript. The study was performed with financial support from the Bundesinstitut für Arzneimittel und Medizinprodukte (German Federal Institute for Drugs and Medical Devices).
Conflict of interest statement
- 2.Adams J (2004) The adverse effect profile of neurobehavioral teratogens: retinoic acid. Birth Defects Res A 70:344Google Scholar
- 3.Adams J, Lammer E (1991) Relationship between dysmorphology and neuropsychological functions in children exposed to isotretinoin (in utero). In: Fujii T, Boer GJ (eds) Functional neuroteratology of short term exposure to drugs. Teiko University Press, Tokyo, pp 159–168Google Scholar
- 9.Holmes LB (1999) Need for inclusion and exclusion criteria for the structural abnormalities recorded in children born from exposed pregnancies. Teratology 64:79–82Google Scholar
- 13.Lammer EJ, Hayes AM, Schunior A et al (1988) Unusually high risk for adverse outcomes of pregnancy following fetal isotretinoin exposure. Am J Hum Genet 43:A 58Google Scholar
- 14.Martinez-Frias ML, Rodriguez-Pinilla E (1999) The problems of using data from teratology information services (TIS) to identify putative teratogens. Teratology 60:54–55. doi: 10.1002/(SICI)1096-9926(199908)60:2<54::AID-TERA3>3.0.CO;2-3 CrossRefPubMedGoogle Scholar
- 19.Ornoy A, Mastroiacovo P (2000) More on data from teratogen information systems (TIS). Teratology 61:327–328. doi: 10.1002/(SICI)1096-9926(200005)61:5<327::AID-TERA2>3.0.CO;2-H CrossRefPubMedGoogle Scholar